Preventative oral vancomycin reduces the incidence of C. difficle during allogeneic hematopoietic stem cell transplantation, according to a study by Pittsburgh-based University of Pennsylvania ...

A 4-week vancomycin pulse and taper regimen may be a safe and effective strategy to delay or prevent Clostridioides difficile ...

Clostridioides difficile (C. difficile) is a leading cause of illness and death, especially for frail and hospitalized Americans. Now, a new study suggests that the leading antibiotic used to fight it ...

Fecal microbiota transplant might be considered for first-line treatment of Clostridioides difficile (C. diff), based on noninferiority findings from a randomized, open-label trial. A similar ...

Fidaxomicin should be the antibiotic of choice when treating adults with Clostridioides difficile infection, according to new guidance from the Infectious Diseases Society of America and the Society ...

Please provide your email address to receive an email when new articles are posted on . FMT appeared as effective as vancomycin in curing first-time C. difficile infection. Findings show FMT has ...

Treatment with ridinilazone was found to significantly decrease the rate of recurrent Clostridioides difficile infection (CDI) compared with vancomycin. Treatment with ridinilazone was found to ...

C. difficile infection recurrence rates were numerically lower with vancomycin than with placebo, though the difference was not significant. However, the results could be clinically meaningful, an ...

A study has linked initial vancomycin monotherapy to higher rates of Clostridium difficile infection in patients with inflammatory bowel disease, according to a report by Internal Medicine News. The ...

The combination of vancomycin and fecal microbiota transplantation was found to be superior to fidaxomicin or vancomycin in the treatment of patients with recurrent Clostridioides (formerly ...

Fecal microbiota transplant was noninferior to vancomycin as the initial treatment for C. diff in a randomized, open-label trial. Transplant showed slightly higher cure rates without recurrence and ...